Ophthotech Corporation (Nasdaq:OPHT) today announced that a subgroup
analysis assessing the development and progression of sub-retinal
fibrosis in the Company's Phase 2b trial comparing Fovista ® (1.5mg)
combination therapy with Lucentis ® (0.5mg) versus Lucentis ®
(0.5mg) monotherapy will be presented at the American Academy of
Ophthalmology 2014 Annual Meeting in Chicago, Illinois.
for - Ophthotech Announces Fovista® Phase 2b Independent Analysis Shows that Fovista® Anti-PDGF Therapy, Combined with Anti-VEGF Therapy, is Associated with a Reduction of Sub-retinal Fibrosis in Wet AMD Patients investment picks